Atlas Trials

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Clinical trial NCT01549886 · TERMINATED

Trial details

NCT number
NCT01549886
Sponsor
Spectrum Pharmaceuticals, Inc
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Hodgkin's Lymphoma
Start date
2011-11-01
Primary completion
2014-06-01
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.